Effect of minocycline ointment on meibomian gland dysfunction in a rat model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The purpose of this study was to evaluate the effectiveness of topical minocycline on meibomian gland dysfunction (MGD) in a rat model and contribute to the understanding of its use for the treatment of MGD.Methods: To establish an MGD rat model, complete Freund’s adjuvant injections were administered. The rats were randomly assigned to six groups (control, control with minocycline, MGD, MGD with minocycline, MGD with oxytetracycline, and MGD with cyclosporine), and each group received treatments twice daily for three weeks. During the experimental period, ocular symptom score assessments, including tear break-up time, meibomian swelling, telangiectasia, and corneal fluorescein staining, were performed and analyzed. After 3 weeks, tissues were gathered, examined under a light microscope, and subjected to immunohistochemistry analysis.Results: The results showed that the minocycline treatment group had a significantly lower fluorescein staining score, lower levels of inflammation in the tissues, and longer tear break-up time compared to the MGD group. The study found that topical minocycline had a positive effect in controlling the level of inflammation in ocular tissues and improving the ocular sign scores compared to the other treatments.Conclusion: The study investigated the potential of topical minocycline in treating MGD and found that it had positive effects in reducing inflammation and improving ocular signs, when compared to other treatments. The main advantages of topical minocycline include the low incidence of side effects and high drug concentrations in the ocular tissues.
Abstract
Background: The purpose of this study was to evaluate the effectiveness of topical minocycline on meibomian gland dysfunction (MGD) in a rat model and contribute to the understanding of its use for the treatment of MGD.Methods: To establish an MGD rat model, complete Freund’s adjuvant injections were administered. The rats were randomly assigned to six groups (control, control with minocycline, MGD, MGD with minocycline, MGD with oxytetracycline, and MGD with cyclosporine), and each group received treatments twice daily for three weeks. During the experimental period, ocular symptom score assessments, including tear break-up time, meibomian swelling, telangiectasia, and corneal fluorescein staining, were performed and analyzed. After 3 weeks, tissues were gathered, examined under a light microscope, and subjected to immunohistochemistry analysis.Results: The results showed that the minocycline treatment group had a significantly lower fluorescein staining score, lower levels of inflammation in the tissues, and longer tear break-up time compared to the MGD group. The study found that topical minocycline had a positive effect in controlling the level of inflammation in ocular tissues and improving the ocular sign scores compared to the other treatments.Conclusion: The study investigated the potential of topical minocycline in treating MGD and found that it had positive effects in reducing inflammation and improving ocular signs, when compared to other treatments. The main advantages of topical minocycline include the low incidence of side effects and high drug concentrations in the ocular tissues.
참고문헌 (30)
- Nichols KK, "The international workshop on meibomian gland dysfunction: executive summary", Invest Ophthalmol Vis Sci, 52, pp.1922~1929 (2011)
- Jester JV, "Meibomian gland dysfunction : hyperkeratinization or atrophy?", BMC Ophthalmol, 15, pp.156~ (2015)
- Foulks GN, "Meibomian gland dysfunction : a clinical scheme for description, diagnosis, classification, and grading", Ocul Surf, 1, pp.107~126 (2003)
- Geerling G, "Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction:proceedings of the OCEAN group meeting", Ocul Surf, 15, pp.179~192 (2017)
- Han D, "Comparative study on the effect of hyperthermic massage and mechanical squeezing in the patients with mild and severe meibomian gland dysfunction : an interventional case series", PLoS One, 16, pp.e0247365~ (2021)
- Doughty MJ, "On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction(MGD)", Cont Lens Anterior Eye, 39, pp.2~8 (2016)
- Yong VW, "The promise of minocycline in neurology", Lancet Neurol, 3, pp.744~751 (2004)
- Fendrich P, "An unusual case of oral pigmentation", Oral Surg Oral Med Oral Pathol, 58, pp.288~289 (1984)
- Agwuh KN, "Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines", J Antimicrob Chemother, 58, pp.256~265 (2006)
- Khatri PM, "Use of minocycline as systemic antimicrobial therapy in refractory periodontitis with chronic gingival enlargement", J Adv Pharm Technol Res, 3, pp.75~79 (2012)
- Lac D, "Topical minocycline formulations : evaluation and comparison of dermal uptake efficacy", Int J Pharm X, 1, pp.100009~ (2019)
- Lee H, "Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction", Am J Ophthalmol, 154, pp.949~957 (2012)
- Kim H, "Effect of 808-nm laser photobiomodulation treatment in blepharitis rat model", Cornea, 40, pp.358~363 (2021)
- Bron AJ, "Grading of corneal and conjunctival staining in the context of other dry eye tests", Cornea, 22, pp.640~650 (2003)
- Labbé A, "Tear film osmolarity in patients treated for glaucoma or ocular hypertension", Cornea, 31, pp.994~999 (2012)
- Hosseini K, "Development and evaluation of a measure of patient-reported symptoms of blepharitis", Health Qual Life Outcomes, 16, pp.11~ (2018)
- Arita R, "Development of definitive and reliable grading scales for meibomian gland dysfunction", Am J Ophthalmol, 169, pp.125~137 (2016)
- Green-Church KB, "The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease", Invest Ophthalmol Vis Sci, 52, pp.1979~1993 (2011)
- McCulley JP, "Meibomian gland function and the tear lipid layer", Ocul Surf, 1, pp.97~106 (2003)
- Liu R, "Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction", Am J Ophthalmol, 183, pp.81~90 (2017)
- Shine WE, "Minocycline effect on meibomian gland lipids in meibomianitis patients", Exp Eye Res, 76, pp.417~420 (2003)
- Zanjani TM, "Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain", Eur J Pharmacol, 538, pp.66~72 (2006)
- Ledeboer A, "Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation", Pain, 115, pp.71~83 (2005)
- Ciancio SG, "An evaluation of minocycline in patients with periodontal disease", J Periodontol, 51, pp.530~534 (1980)
- Vu CHV, "Influence of meibomian gland dysfunction and friction-related disease on the severity of dry eye", Ophthalmology, 125, pp.1181~1188 (2018)
- Arita R, "Linoleic acid content of human meibum is associated with telangiectasia and plugging of gland orifices in meibomian gland dysfunction", Exp Eye Res, 145, pp.359~362 (2016)
- Asadi A, "Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness : back to the future", J Glob Antimicrob Resist, 22, pp.161~174 (2020)
- Ji YW, "Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye", Invest Ophthalmol Vis Sci, 54, pp.7557~7566 (2013)
- Wu X, "Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction", Int Ophthalmol, 40, pp.3049~3058 (2020)
- Martins AM, "A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea", Antibiotics(Basel), 10, pp.757~ (2021)